Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05217927 · ClinicalTrials.gov registry record · Phase 4
Efficacy and Safety Study of Rimegepant in Episodic Migraine Prevention With Multiple Dosing Regimens
A Phase 4 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 4
- Development phase
- 1,415
- Enrollment target
NCT05217927: Completed Phase 4 study, sponsored by Pfizer.
NCT05217927 is a Phase 4 study that has completed, run by Pfizer. The registered enrollment target is 1,415 participants, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (173% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05217927, a Phase 4 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 1,415 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the efficacy and safety of daily and every other day dosing of rimegepant to placebo as a preventive treatment for episodic migraine.
Primary Outcome
A migraine day was defined as any calendar day in which the participant experienced a qualified migraine headache (onset, continuation, or recurrence of the migraine headache). A qualified migraine headache was defined as a migraine with or without aura, lasting for \>=30 minutes, and meeting either \>=2 of the pain features: unilateral location; pulsating quality; moderate or severe pain intensity; aggravation by or causing avoidance of routine physical activity OR \>=1 of the associated sympto
Interventions
- DRUG Rimegepant 75mg daily dosing
- DRUG Rimegepant 75mg every other day dosing
- DRUG Placebo comparator dosing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,415 participants |
| Start Date | 2022-03-04 |
| Est. Completion | 2024-12-11 |
| Phase | Phase 4 |
What the finished NCT05217927 record still lists
NCT05217927 is an interventional study that assigns participants to a tested intervention. Its 1,415 participants enrollment target places it among the larger protocols in the corpus, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (173% higher).
The record links to 0 conditions, and to 3 interventions - of which Rimegepant 75mg daily dosing is the first listed.
NCT05217927 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05217927 about?
NCT05217927 is a clinical study titled "Efficacy and Safety Study of Rimegepant in Episodic Migraine Prevention With Multiple Dosing Regimens". The purpose of this study is to compare the efficacy and safety of daily and every other day dosing of rimegepant to placebo as a preventive treatment for episodic migraine.
What is the current status of trial NCT05217927?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 1,415 participants. The study started on 2022-03-04. Estimated completion is 2024-12-11.
What interventions are being tested in trial NCT05217927?
The interventions under investigation include: Rimegepant 75mg daily dosing (DRUG), Rimegepant 75mg every other day dosing (DRUG), Placebo comparator dosing (DRUG).
Who is sponsoring clinical trial NCT05217927?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05217927's enrollment target sits among peer trials
1,415 54th of 2000 higher than 1,947 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05890404 · 1,410 participants · NA
SGM Evidenced-Based Mental Healthcare Implementation
- NCT07042451 · 1,410 participants · NA
An Evaluation of the Pink Cloud Application in Post- Treatment Substance Use Disorder Support
- NCT07222566 · 1,410 participants · Phase 3
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- NCT05992935 · 1,405 participants · Phase 1
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI